Pandorum Technologies Private Limited, a active private limited company, was established on 16 May 2011 in Bengaluru, Karnataka, India. Engaging in healthtech & medical tech solutions within the professional, scientific and technical sector, it holds CIN: U72200KA2011PTC058650. Registered under ROC Roc Bangalore. it is unlisted. It has an authorized capital of ₹4.76 Cr and a paid-up capital of ₹4.67 Cr.
It upholds a compliant status. Employing 27 professional, Its leadership includes Manish Kumar Belmannu (Nominee Director), Arun Chandru Raja (Director), Tuhin Bhowmick (Director). Past directors included Pratik Bose, Saurabh Srivastava, Sonal Asthana. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at Egf 4 & 5, Bangalore Bioinnovation Centre, Helix Biotech Park, Electronic City Phas, E 1,, Bengaluru, Karnataka, 560100.
U72200KA2011PTC058650
058650
16 May 2011
₹4.76 Cr
₹4.67 Cr
Roc Bangalore
Unlisted
Active
Explore comprehensive insights into Pandorum Technologies Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Manish Kumar Belmannu | Nominee Director | 18 Jul 2018 | Current |
| Arun Chandru Raja | Director | 16 May 2011 | Current |
| Tuhin Bhowmick | Director | 16 May 2011 | Current |
| Sailesh Tulshan | Director | 10 Aug 2018 | Current |
| Sudipta Gautam | Nominee Director | 18 Dec 2019 | Current |
| Sonal Asthana | Director | 14 Nov 2016 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 19 Sep 2019 | Past |
| Pramod Abcsdd | Nominee Director | 18 Dec 2019 | Past |
| Pramod Abcsdd | Additional Director | 29 Sep 2017 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Pandorum Technologies Private Limited, for the financial year ended 2024, experienced significant growth in revenue, with a 301.44% increase. The company also saw a substantial improvement in profitability, with a 19.88% increase in profit. The company's net worth Soared by an impressive increase of 170.79%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2024, Pandorum Technologies had a promoter holding of 84.86% and a public holding of 15.15%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Pandorum Technologies has a workforce of 27 employees as of Dec 13, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Pandorum Technologies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pandorum Technologies's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Pandorum Technologies Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was recorded as a recent event.
Progress on Pandorum Technologies Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Bangalore. was documented.
Sudipta Gautam was appointed as a Nominee Director was appointed as a Nominee Director on 18 Dec 2019 & has been associated with this company since 5 years 11 months . was recorded as a recent event.
The activity Sailesh Tulshan was appointed as a Director was appointed as a Director on 10 Aug 2018 & has been associated with this company since 7 years 4 months . was completed.
The activity Manish Kumar Belmannu was appointed as a Nominee Director was appointed as a Nominee Director on 18 Jul 2018 & has been associated with this company since 7 years 4 months . was completed.
Progress on Sonal Asthana was appointed as a Director was appointed as a Director on 14 Nov 2016 & has been associated with this company since 9 years 30 days . was documented.
PRNewswireBengaluru (Karnataka) [India], March 15: Pandorum Technologies, a leading biotechnology company, announced today the successful closure of a pre-Series B funding round, securing USD 11 million (INR 88 crore) in investment. The funding was sourced from Mr. Ashish Kacholia, Everest Finance Investment, Acebright Pharma and Ms. Bandana Kankani's syndicate along with existing investors Mr. Sunil Kant Munjal and the Indian Angel Network.Founded by Arun Chandru & Dr. Tuhin Bhowmick, the startup company focuses on Tissue Engineering and Regenerative Medicine. With the current round of funding, Pandorum aims to progress towards the First-in-Human study of its Flagship product Kuragenx- the 'Liquid Cornea', to treat corneal blindness. The funding will also allow the company to advance its tunable technology platform that has demonstrated regenerative potential beyond cornea, such as, for liver, lung and neuronal tissues."We are thrilled to have the support of the notable investors, including Mr. Ashish Kacholia- as we continue to innovate and develop therapeutics to restore healthy tissue functions, in order to help the patients suffering from unmet clinical needs. Our flagship product Kuragenx combines proprietary biomaterials with regenerative nanotherapy, guiding the formation of a functional corneal tissue to restore vision. This is a First-in-Class approach that can truly blur the line between treatment and cure" said Dr. Tuhin Bhowmick, Co-Founder & CEO of Pandorum Technologies.Mr. Ashish Kacholia said, "This startup is working on cure for corneal blindness. Though the journey to commercialization is long, amazing payoffs possible for all mankind. Indian science and scientific community making amazing strides.""There's a paradigm shift happening in the Indian biotech and lifescience sector with deep-tech companies like Pandorum pushing boundaries and creating global innovations. My best wishes to the team for what they have set out to accomplish," said Ms. Bandana Kankani from Nexxtmile who invested and also advised on this funding round."It is inspiring to see a company originating from India started by two young founders poised to change the landscape of cornea transplant and blindness in the world. We are glad to support the team as they navigate the path towards commercializing their cornea regeneration platform, Kuragenx," said Mr. Ashish Sheth - Partner at Orbit Financial Capital (OFC). OFC acted as buyside advisor to Acebright Pharma.Corneal opacity is one of the major causes of blindness worldwide, with millions waiting for donor tissues against significant odds. Pandorum's Kuragenx promotes scarless regeneration of cornea tissue to restore vision, as demonstrated in extensive pre-clinical studies. In 2023, Kuragenx was awarded the Orphan Drug Designation by the USFDA, for the treatment of Neurotrophic Keratitis, a form of ulcerative corneal blindness that is currently untreatable or extremely difficult to treat. Pandorum is currently engaged in clinical manufacturing process and IND enabling studies of Kuragenx, with the aim towards the first patient dosing in 2025, after obtaining due regulatory approvals."Giving back vision with something made in the lab, without depending on donor corneas, is truly transformative. Kudos to our team at Pandorum. Could not have been possible without the support of our investors, partners and the Government enabled R&D ecosystem. Indeed, it's a multi-billion dollar global opportunity; more so, this will positively impact millions of lives," said Arun Chandru, Co-Founder & Director of the company.Pandorum has its R&D labs in Bangalore, India and in the Bay Area, San Francisco, USA, and works with prominent global partners. The company has received competitive grants from the Department of Biotechnology, Government of India, and has previously raised funds from marquee investors and VCs including Sunil Kant Munjal, Binny Bansal, T K Kurien, Sachin Bansal, 021 Capital, Indian Angel Network (IAN) Fund, Karnataka Venture Fund (KITVEN), Kotak Investment Advisors and 500 Startups.For more information, visit www.pandorum.comLogo: https://mma.prnewswire.com/media/2362884/Pandorum_Logo.jpg(ADVERTORIAL DISCLAIMER: The above press release has been provided by PRNewswire.will not be responsible in any way for the content of the same)Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor.
India's biotech startups making global impact despite challenges. Bugworks beats superbugs with new antibiotics, Pandorum 3D-prints human tissues for medical research. Both win ET Startup Awards. Bugworks CEO humbled, says last antibiotic breakthrough in 1984. Pandorum aims to make personalized organs. Both funded by BIRAC. Biocon's Kiran Mazumdar-Shaw impressed. Tough for biotech to scale up, but grateful for Indian ecosystem..
The CIN of Pandorum Technologies Private Limited is U72200KA2011PTC058650.
Pandorum Technologies Private Limited is headquartered at Egf 4 & 5, Bangalore Bioinnovation Centre, Helix Biotech Park, Electronic City Phas, E 1,, Bengaluru, Karnataka, 560100.
Pandorum Technologies Private Limited was incorporated on 16 May 2011.
The current directors of Pandorum Technologies Private Limited are
The primary industry of Pandorum Technologies Private Limited is Professional, Scientific And Technical.
Pandorum Technologies Private Limited is unlisted.
The authorized capital of Pandorum Technologies Private Limited is ₹4.76 Cr, and the paid-up capital is ₹4.67 Cr.
The compliance status of Pandorum Technologies Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX